Processa Pharmaceuticals, Inc. (PCSA) Stock Score, Valuation & Financial Research

Processa Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PCSA

Processa Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.68. These figures are a research snapshot, not a buy or sell recommendation.

What Processa Pharmaceuticals, Inc. does

Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing drug candidates to improve the safety and efficacy of existing treatments. The company operates as a development-stage enterprise and does not currently generate revenue from product sales, relying instead on capital raises and financing activities to fund its research and development operations.

Products and services

  • The company's product pipeline includes clinical-stage assets such as PCS6422, an oncology candidate, and other therapeutic programs aimed at addressing unmet medical needs through regulatory-focused development strategies.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract research organizations and contract manufacturing organizations to conduct clinical trials, manufacture drug supplies, and provide laboratory services. Specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Regulatory-focused development strategy aimed at improving existing drug therapies. Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing to continue operations. Source
  • Reliance on third-party service providers for clinical trials and manufacturing. Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PCSA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.68
Market capitalization:
4.7M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -13.44M
Free cash flow:
USD -11.39M
Cash:
USD 196.33K
Total debt:
USD 0.00
EPS:
USD -5.60

What stands out

  • Free cash flow is USD -11.39M, negative for the stored period.
  • The balance sheet shows USD 196.33K of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 196.33K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PCSA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PCSA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is PCSA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PCSA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PCSA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research PCSA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.